» Articles » PMID: 15843611

Selective Glial Cell Line-derived Neurotrophic Factor Production in Adult Dopaminergic Carotid Body Cells in Situ and After Intrastriatal Transplantation

Overview
Journal J Neurosci
Specialty Neurology
Date 2005 Apr 22
PMID 15843611
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Glial cell line-derived neurotrophic factor (GDNF) exerts a notable protective effect on dopaminergic neurons in rodent and primate models of Parkinson's disease (PD). The clinical applicability of this therapy is, however, hampered by the need of a durable and stable GDNF source allowing the safe and continuous delivery of the trophic factor into the brain parenchyma. Intrastriatal carotid body (CB) autografting is a neuroprotective therapy potentially useful in PD. It induces long-term recovery of parkinsonian animals through a trophic effect on nigrostriatal neurons and causes amelioration of symptoms in some PD patients. Moreover, the adult rodent CB has been shown to express GDNF. Here we show, using heterozygous GDNF/lacZ knock-out mice, that unexpectedly CB dopaminergic glomus, or type I, cells are the source of CB GDNF. Among the neural or paraneural cells tested, glomus cells are those that synthesize and release the highest amount of GDNF in the adult rodent (as measured by standard and in situ ELISA). Furthermore, GDNF expression by glomus cells is maintained after intrastriatal grafting and in CB of aged and parkinsonian 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated animals. Thus, glomus cells appear to be prototypical abundant sources of GDNF, ideally suited to be used as biological pumps for the endogenous delivery of trophic factors in PD and other neurodegenerative diseases.

Citing Articles

Carotid Body and Cell Therapy.

Lazarov N, Atanasova D Adv Anat Embryol Cell Biol. 2023; 237:155-159.

PMID: 37946082 DOI: 10.1007/978-3-031-44757-0_10.


Extracellular matrix protein anosmin-1 overexpression alters dopaminergic phenotype in the CNS and the PNS with no pathogenic consequences in a MPTP model of Parkinson's disease.

Villadiego J, Garcia-Swinburn R, Garcia-Gonzalez D, Lebron-Galan R, Murcia-Belmonte V, Garcia-Roldan E Brain Struct Funct. 2023; 228(3-4):907-920.

PMID: 36995433 PMC: 10147818. DOI: 10.1007/s00429-023-02631-0.


Protection and Repair of the Nigrostriatal Pathway with Stem-Cell-Derived Carotid Body Glomus Cell Transplants in Chronic MPTP Parkinsonian Model.

Villadiego J, Munoz-Manchado A, Sobrino V, Bonilla-Henao V, Suarez-Luna N, Ortega-Saenz P Int J Mol Sci. 2023; 24(6).

PMID: 36982650 PMC: 10057403. DOI: 10.3390/ijms24065575.


Cellular basis of learning and memory in the carotid body.

Gold O, Bardsley E, Ponnampalam A, Pauza A, Paton J Front Synaptic Neurosci. 2022; 14:902319.

PMID: 36046221 PMC: 9420943. DOI: 10.3389/fnsyn.2022.902319.


Combined cell-based therapy strategies for the treatment of Parkinson's disease: focus on mesenchymal stromal cells.

Rodriguez-Pallares J, Garcia-Garrote M, Parga J, Labandeira-Garcia J Neural Regen Res. 2022; 18(3):478-484.

PMID: 36018150 PMC: 9727452. DOI: 10.4103/1673-5374.350193.


References
1.
Batchelor P, Liberatore G, Wong J, Porritt M, Frerichs F, Donnan G . Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci. 1999; 19(5):1708-16. PMC: 6782182. View

2.
Miyazaki H, Okuma Y, Fujii Y, Nagashima K, Nomura Y . Glial cell line-derived neurotrophic factor protects against delayed neuronal death after transient forebrain ischemia in rats. Neuroscience. 1999; 89(3):643-7. DOI: 10.1016/s0306-4522(98)00592-2. View

3.
Luquin M, Montoro R, Guillen J, Saldise L, Insausti R, Del Rio J . Recovery of chronic parkinsonian monkeys by autotransplants of carotid body cell aggregates into putamen. Neuron. 1999; 22(4):743-50. DOI: 10.1016/s0896-6273(00)80733-3. View

4.
Kordower J, Palfi S, Chen E, Ma S, Sendera T, Cochran E . Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol. 1999; 46(3):419-24. DOI: 10.1002/1531-8249(199909)46:3<419::aid-ana21>3.0.co;2-q. View

5.
Lipton J, Ling Z, Vu T, Robie H, Mangan K, Weese-Mayer D . Prenatal cocaine exposure reduces glial cell line-derived neurotrophic factor (GDNF) in the striatum and the carotid body of the rat: implications for DA neurodevelopment. Brain Res Dev Brain Res. 1999; 118(1-2):231-5. DOI: 10.1016/s0165-3806(99)00127-3. View